For me, my biggest concern was bad news on the CLBP coming out before what I am convinced (given the data already out there) will be a run of share boosting good news on Heart, Ards and srGvHD.
This result is not bad news and there is a pathway to commercialisation that will become clearer in the coming months. So whether we bump down or up a little, so what, the tide is turning quickly and it’s turning in our favour. 2021 will be a momentous year.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-141
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |